Assessment of bronchial and pulmonary blood supply in non-small cell lung cancer subtypes using computed tomography perfusion

Investigative Radiology

Volumn 50, Issue 3, 2015, Pages 179-186

  Nguyen Kim, Thi Dan Linh ^a   Frauenfelder, Thomas ^a   Strobel, Klaus ^b   Veit Haibach, Patrick ^a,c   Huellner, Martin W ^c  

^a University Hospital Zurich Institut fur Diagnostische Radiologie   (Switzerland)

^b LUZERNER KANTONSSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

computed tomography; lung neoplasms; medical oncology; multimodal imaging; perfusion

Indexed keywords

IOPROMIDE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY PERFUSION; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG BLOOD VESSEL; LUNG BLOOD VOLUME; LUNG PERFUSION; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SQUAMOUS CELL LUNG CARCINOMA; TUMOR VOLUME; VASCULARIZATION; ALGORITHM; ANGIOGRAPHY; BLOOD FLOW VELOCITY; CLASSIFICATION; COMPUTER ASSISTED DIAGNOSIS; IMAGE ENHANCEMENT; LUNG CIRCULATION; LUNG TUMOR; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PROCEDURES; RADIOGRAPHY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALGORITHMS; ANGIOGRAPHY; BLOOD FLOW VELOCITY; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMAGE ENHANCEMENT; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PULMONARY CIRCULATION; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84923685116     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000124     Document Type: Article

References (48)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014
2. Kaira K, Tomizawa Y, Yoshino R, et al. Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer. Lung Cancer. 2013; 82: 103-108
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330-353
4. Di Costanzo F, Mazzoni F, Micol Mela M, et al. Bevacizumab in non-small cell lung cancer. Drugs. 2008; 68: 737-746
5. Drevs J, Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-Tumour agents targeting angiogenesis. J Intern Med. 2006; 260: 517-529
6. Ng QS, Goh V. Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography. J Thorac Imaging. 2010; 25: 142-150
7. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004; 22: 4442-4445
8. Goh V, NgQS, Miles K.computed tomography perfusion imaging for therapeutic assessment: has it come of age as a biomarker in oncology? Invest Radiol. 2012; 47: 2-4
9. Fraioli F, Anzidei M, Zaccagna F, et al.Whole-Tumor perfusion CTin patientswith advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology. 2011; 259: 574-582
10. Jiang T, Kambadakone A, Kulkarni NM, et al. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol. 2012; 47: 11-17
11. Ng QS, Goh V, Klotz E, et al. Quantitative assessment of lung cancer perfusion usingMDCT: does measurement reproducibility improve with greater tumor volume coverage? AJR Am J Roentgenol. 2006; 187: 1079-1084
12. Reiner CS, Goetti R, Eberli D, et al. CT perfusion of renal cell carcinoma: impact of volume coverage on quantitative analysis. Invest Radiol. 2012; 47: 33-40
13. Morsbach F, Pfammatter T, Reiner CS, et al.computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases. Invest Radiol. 2013; 48: 787-794
14. Choi SH, Chung JW, Kim HC, et al. The role of perfusion CTas a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. Invest Radiol. 2010; 45: 427-436
15. Cyran CC, von Einem JC, Paprottka PM, et al. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. Invest Radiol. 2012; 47: 49-57
16. Milne EN. Circulation of primary and metastatic pulmonary neoplasms: a postmortem microarteriographic study. Am J Roentgenol Radium Ther Nucl Med. 1967; 100: 603-619
17. Goetti R, Leschka S, Desbiolles L, et al. Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Invest Radiol. 2010; 45: 419-426
18. Bisdas S, Baghi M, Smolarz A, et al. Quantitative measurements of perfusion and permeability of oropharyngeal and oral cavity cancer, recurrent disease, and associated lymph nodes using first-pass contrast-enhanced computed tomography studies. Invest Radiol. 2007; 42: 172-179
19. Tacelli N, Santangelo T, Scherpereel A, et al. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-Angiogenic chemotherapy. Eur Radiol. 2013; 23: 2127-2136
20. Miles KA, Griffiths MR, Fuentes MA. Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules. Radiology. 2001; 220: 548-553
21. Li Y, Yang ZG, Chen TW, et al. First-pass perfusion imaging of solitary pulmonary nodules with 64-detector row CT: comparison of perfusion parameters of malignant and benign lesions. Br J Radiol. 2010; 83: 785-790
22. Yuan X, Zhang J, Quan C, et al. Differentiation of malignant and benign pulmonary nodules with first-pass dual-input perfusion CT. Eur Radiol. 2013; 23: 2469-2474
23. Cronin P, Dwamena BA, Kelly AM, et al. Solitary pulmonary nodules: metaanalytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology. 2008; 246: 772-782
24. Shi J, Schmid-Bindert G, Fink C, et al. Dynamic volume perfusion CT in patients with lung cancer: baseline perfusion characteristics of different histological subtypes. Eur J Radiol. 2013; 82: e894-e900
25. Tacelli N, Remy-Jardin M, Copin MC, et al. Assessment of non-small cell lung cancer perfusion: pathologic-CT correlation in 15 patients. Radiology. 2010; 257: 863-871
26. Spira D, Neumeister H, Spira SM, et al. Assessment of tumor vascularity in lung cancer using volume perfusion CT (VPCT) with histopathologic comparison: a further step toward an individualized tumor characterization. J Comput Assist Tomogr. 2013; 37: 15-21
27. Huellner MW, Collen TD, Gut P, et al. Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT. EJNMMI Res. 2014; 4: 6
28. Lee SM, Lee HJ, Kim JI, et al. Adaptive 4D volume perfusion CTof lung cancer: effects of computerized motion correction and the range of volume coverage on measurement reproducibility. AJR Am J Roentgenol. 2013; 200: W603-W609
29. Ippolito D, Capraro C, Casiraghi A, et al. Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging. Eur Radiol. 2012; 22: 803-811
30. Sauter AW, Winterstein S, Spira D, et al. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT. J Nucl Med. 2012; 53: 521-529
31. Ng CS, Chandler AG, Wei W, et al. Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. AJR Am J Roentgenol. 2011; 197: 113-121
32. Travis WD. Lung tumours with neuroendocrine differentiation. Eur J Cancer. 2009; 45(suppl 1): 251-266
33. Grand B, Cazes A, Mordant P, et al. High grade neuroendocrine lung tumors: pathological characteristics, surgical management and prognostic implications. Lung Cancer. 2013; 81: 404-409
34. TravisW, Brambilla E, Muller-Hermelink H, et al. Tumours of the lung, pleura thymus and heart. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2004: 9-124
35. Rossi G, Mengoli MC, Cavazza A, et al. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch. 2014; 464: 61-68
36. Fraioli F, Anzidei M, Serra G, et al. Whole-Tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-Angiogenetic chemotherapy effects. Br J Radiol. 2013; 86: 20120174
37. Kiessling F, Boese J, Corvinus C, et al. Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol. 2004; 14: 1226-1233
38. TsaiCH, Lin CM, Hsieh CC, et al. Tumor volume is a better prognostic factor than greatest tumor diameter in stage Ia non-small cell lung cancer. Thorac Cardiovasc Surg. 2006; 54: 537-543
39. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000; 18: 1135-1149
40. Gonsalves CF, Brown DB. Chemoembolization of hepatic malignancy. Abdom Imaging. 2009; 34: 557-565
41. Vogl TJ, Shafinaderi M, Zangos S, et al. Regional chemotherapy of the lung: transpulmonary chemoembolization in malignant lung tumors. Semin Intervent Radiol. 2013; 30: 176-184
42. Vogl TJ, Wetter A, Lindemayr S, et al. Treatment of unresectable lung metastases with transpulmonary chemoembolization: preliminary experience. Radiology. 2005; 234: 917-922
43. Lindemayr S, Lehnert T, Korkusuz H, et al. Transpulmonary chemoembolization: a novel approach for the treatment of unresectable lung tumors. Tech Vasc Interv Radiol. 2007; 10: 114-119
44. Vogl TJ, Herzog C, Zangos S, et al. Palliative treatment of primary lung tumors with transpulmonary chemoembolization (TPCE). Rofo. 2007; 179: 300-307
45. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247
46. Wang J, Wu N, Cham MD, et al. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol. 2009; 193: 1090-1096
47. Lind JS, MeijerinkMR, Dingemans AM, et al. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol. 2010; 20: 2890-2898
48. Ren Y, Fleischmann D, Foygel K, et al. Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice. Invest Radiol. 2012; 47: 25-32